Alnylam Gets EU Approval for AMVUTTRA in ATTR Amyloidosis
First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of Wild-Type or Hereditary ATTR Amyloidosis with Cardiomyopathy – Novel RNAi Mechanism...
Category : Clinical Research, Pharma & Healthcare Financing
Innoviva Files for Zoliflodacin, a New Oral Antibiotic for Gonorrhea
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that...
Neutrinos Launches AI-Powered Life & Health Claims Automation Suite
New solutions apply AI across intake, triage, adjudication, and fraud detection, enabling intelligent automation for life & health insurance claims Neutrinos, a leader in AI-powered intelligent automation...
Everest Medicines Shares Positive Early Data on BTK Inhibitor EVER001
Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced...
Tracer Biotech Partners with QIAGEN to Advance Blood MRD Testing
Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA)...
Preliminary Data from Two ADC Trials Presented at 2025 ASCO Meeting
The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio presented the preliminary data of two clinical trials, HER3...
Fujirebio Launches Lumipulse G sTREM2 Neuro Test for Research
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G...
Pacific Prime Supports Children’s Heart Care with Rende Fund
Pacific Prime, a global health insurance intermediary group in international health insurance and employee benefits solutions, is proud to announce that two children with heart disease, financially assisted by...
XellSmart Gets FDA Clearance for 3 Phase I INDs in CNS Cell Therapies
XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has...
ImmunAbs Gets FDA Phase 2 IND OK for IM-101 in Myasthenia Gravis
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug...
Bruker Unveils timsUltra AIP with Extreme Sensitivity for Proteomics
Breakthrough Athena Ion Processor (AIP) delivers up to 35% more peptide and 20% more protein identifications for highest sensitivity proteomics At the 73rd Conference on Mass...
BioVaxys, Horizon Amend Asset Purchase Agreement
The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets BioVaxys Technology Corp. is pleased to announce today that the Company and Horizon...
Integrity, Premiere Senior Advisors Partner to Support Seniors
Premiere Senior Advisors will utilize Integrity’s innovative technology and transformative resources to help its agents better anticipate and meet the evolving needs of senior clients ...
PepGen Shifts Focus to DM1 Program After PGN-EDO51 Update
– PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs – – PGN-EDO51 at 10 mg/kg was...
InnoCare Gets OK to Trial Mesutoclax for MDS in China
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND)...